First Time Loading...
N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 13.7 CNY 5.14% Market Closed
Updated: May 5, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Wall Street analysts forecast Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Nanjing King-friend Biochemical Pharmaceutical Co Ltd is 16.64 CNY with a low forecast of 15.79 CNY and a high forecast of 17.85 CNY.

Lowest Forecast
Wall Street Target
15.79 CNY
15% Upside
Average Forecast
Wall Street Target
16.64 CNY
21% Upside
Highest Forecast
Wall Street Target
17.85 CNY
30% Upside
Lowest
Price Target
15.79 CNY
15% Upside
Average
Price Target
16.64 CNY
21% Upside
Highest
Price Target
17.85 CNY
30% Upside
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors:
Price Targets
001630
Chongkundang Holdings Corp
15% Upside
SCTL
Societal CDMO Inc
2% Upside
K
102940
Kolon Life Science Inc
503% Upside
O
ORNBV
Orion Oyj
10% Upside
001630
Chongkundang Holdings Corp
15% Upside
SCTL
Societal CDMO Inc
2% Upside
K
102940
Kolon Life Science Inc
503% Upside
O
ORNBV
Orion Oyj
10% Upside
W
016580
Whanin Pharm Co Ltd
49% Upside
524731
Jenburkt Pharmaceuticals Ltd
38% Downside
K
KILITCH
Kilitch Drugs (India) Ltd
34% Upside
IKNA
Ikena Oncology Inc
531% Upside

Revenue
Forecast

Revenue Estimate
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

For the last 7 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's revenue is 34%. The projected CAGR for the next 3 years is 22%.

34%
Past Growth
22%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

For the last 7 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's operating income is 47%. The projected CAGR for the next 3 years is 39%.

47%
Past Growth
39%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Nanjing King-friend Biochemical Pharmaceutical Co Ltd

For the last 7 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's net income is 43%. The projected CAGR for the next 3 years is 18%.

43%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's stock price target?
Price Target
16.64 CNY

According to Wall Street analysts, the average 1-year price target for Nanjing King-friend Biochemical Pharmaceutical Co Ltd is 16.64 CNY with a low forecast of 15.79 CNY and a high forecast of 17.85 CNY.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
22%

For the last 7 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's revenue is 34%. The projected CAGR for the next 3 years is 22%.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
39%

For the last 7 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's operating income is 47%. The projected CAGR for the next 3 years is 39%.

What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
18%

For the last 7 years the compound annual growth rate for Nanjing King-friend Biochemical Pharmaceutical Co Ltd's net income is 43%. The projected CAGR for the next 3 years is 18%.

ALPHA SPREAD
Join more than 134,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.